Literature DB >> 18937302

Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study.

Shivva Vittal1, Ramesh Ganneboina, Buddhadev Layek, Ravi Kumar Trivedi, Kishore Kumar Hotha, D Vijaya Bharathi, Ramesh Mullangi.   

Abstract

A highly sensitive, rapid assay method has been developed and validated for the estimation of omeprazole (OPZ) in human plasma with liquid chromatography coupled to tandem mass spectrometry with electrospray ionization in the positive-ion mode. The assay procedure involves alkalinization of plasma followed by simple liquid-liquid extraction of OPZ and lansoprazole (internal standard, IS) from human plasma with acetonitrile. Chromatographic separation was achieved with 0.01 M ammonium acetate:acetonitrile (40:60, v/v) at a flow rate of 0.25 mL/min on an Inertsil ODS 3 column with a total run time 2.5 min. The MS/MS ion transitions monitored were 346.1 --> 198.1 for OPZ and 370.1 --> 252.1 for IS. Method validation and clinical sample analysis were performed as per FDA guidelines and the results met the acceptance criteria. The lower limit of quantitation achieved was 0.05 ng/mL and the linearity was observed from 0.05 to 10.0 ng/mL. The intra-day and inter-day precisions were in the ranges 2.09-8.56 and 5.29-8.19%, respectively. This novel method has been applied to a pharmacokinetic study of OPZ in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18937302     DOI: 10.1002/bmc.1129

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  2 in total

1.  Complexity in estimation of esomeprazole and its related impurities' stability in various stress conditions in low-dose aspirin and esomeprazole magnesium capsules.

Authors:  Palavai Sripal Reddy; Kishore Kumar Hotha; Shakil Sait
Journal:  Sci Pharm       Date:  2013-02-18

2.  Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer.

Authors:  Gab-Jin Park; Soo Hyeon Bae; Wan-Su Park; Seunghoon Han; Min-Ho Park; Seok-Ho Shin; Young G Shin; Dong-Seok Yim
Journal:  Drug Des Devel Ther       Date:  2017-03-30       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.